Techorizon Launches Feasibility Study Performance Electronic Tool
Verona, Italy-based technology company Techorizon, announced the launch of FeRMI, an electronic application to advance the conduct of clinical trial feasibility studies.
Verona, Italy-based technology company Techorizon, announced the launch of FeRMI, an electronic application to advance the conduct of clinical trial feasibility studies. Feasibility studies have been largely been paper or email based and are typically not integrated with other databases.
FeRMI creates an entirely integrated, electronic approach to the conduct of feasibility studies and promotes faster, more effective study planning. Each step of the process is managed electronically, with data collection from sites completed via highly customizable online surveys which include real time error checks. The investigator database module speeds selection of potential sites and tracks previous contacts and historical study performance. A real-time reporting module allows users to track trends emerging from the feasibility study whilst in progress, and ultimately to make better decisions about site selection.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
